Leslie Harrold to Drug Therapy, Combination
This is a "connection" page, showing publications Leslie Harrold has written about Drug Therapy, Combination.
Connection Strength
0.424
-
Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.
Score: 0.215
-
Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015 Sep 18; 17:256.
Score: 0.113
-
Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1114-1124.
Score: 0.042
-
Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold LR, Richter S, Guerette B, Mease PJ. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. J Rheumatol. 2021 05; 48(5):693-697.
Score: 0.040
-
Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, Auger JC, Garber LA, Cadoret C, Fish LS, Garber LD, Kelleher M, Bates DW. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004 Aug; 52(8):1349-54.
Score: 0.013